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There is ample evidence that genetic factors play an important role in anxiety disorders. In
support, human genome-wide association studies have implicated several novel candidate
genes. However, illumination of such genetic factors involved in anxiety disorders has not
resulted in novel drugs over the past decades. A complicating factor is the heterogeneous
classiﬁcation of anxiety disorders in the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) and diverging operationalization of anxiety used in preclinical and
clinical studies. Currently, there is an increasing focus on the gene × environment (G × E)
interaction in anxiety as genes do not operate in isolation and environmental factors have
been found to signiﬁcantly contribute to the development of anxiety disorders in at-risk
individuals. Nevertheless, extensive research on G × E mechanisms in anxiety has not
resulted inmajor breakthroughs in drug discovery. Modiﬁcation of individual genes in rodent
models has enabled the speciﬁc study of anxiety in preclinical studies. In this context, two
extensively studied neurotransmitters involved in anxiety are the gamma-aminobutyric acid
(GABA) and 5-HT (5-hydroxytryptamine) system. In this review, we illustrate the complex
interplay between genes and environment in anxiety processes by reviewing preclinical and
clinical studies on the serotonin transporter (5-HTT), 5-HT1A receptor, 5-HT2 receptor, and
GABAA receptor. Even though targets from the serotonin and GABA system have yielded
drugs with known anxiolytic efﬁcacy, the relation between the genetic background of these
targets and anxiety symptoms and development of anxiety disorders is largely unknown.
The aim of this review is to show the vast complexity of genetic and environmental factors in
anxiety disorders. In light of the difﬁcultywithwhich common genetic variants are identiﬁed
in anxiety disorders, animal models with translational validity may aid in elucidating the
neurobiological background of these genes and their possible role in anxiety.We argue that,
in addition to human genetic studies, translational models are essential to map anxiety-
related genes and to enhance our understanding of anxiety disorders in order to develop
potentially novel treatment strategies.
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INTRODUCTION
Anxiety disorders constitute one of the most prevalent classes
of psychiatric disorders. Anxiety disorders in the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) include panic
disorder (PD), generalized anxiety disorder (GAD),phobias, social
phobia, obsessive compulsive disorder (OCD), and post-traumatic
stress disorder (PTSD) and were the most common mental dis-
orders within Europe in 2010 with 14% prevalence (Wittchen,
2011). The heterogeneous classiﬁcation system of individual anx-
iety disorders in the DSM-IV is based on symptomatology rather
than etiology (Friedman et al., 2011). Anxiety disorders are often
comorbid with other psychiatric disorders such as mood disorders
and substance abuse disorders which make anxiety disorders in
general a heterogeneous class of psychiatric disorders. More-
over, speciﬁc anxiety disorders are often incomparable to each
other with regard to the symptomatology. Speciﬁcally, OCD and
PTSD are quite different with regard to their symptomatology
compared to GAD or social phobia. Application of the DSM-V
has not resulted in major changes in the classiﬁcation of anxi-
ety disorders (Friedman et al., 2011). The complex and speciﬁc
classiﬁcation of anxiety disorders may eventually hinder drug
development as one-to-one translation to preclinical models is
not possible. A classiﬁcation based on the neurobiological mecha-
nisms underlying pathological anxiety (intermediate phenotypes)
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has been proposed as a novel strategy to discover novel targets to
treat anxiety symptoms (Ressler and Mayberg, 2007). However,
so far, progress in understanding the neurobiology of emotional
(dys)regulation has not resulted in novel treatments. Another
approach is based on the hypothesis of dysfunctional neurotrans-
mitter systems,which assumes that anxiety disorders are associated
with abnormal functionality of speciﬁc neurotransmitter systems.
However, the deﬁnition of a“dysfunctional”neurotransmitter sys-
tem is difﬁcult and not without confounds, and even more, a
direct and consistent relation between speciﬁc neurotransmitters
systems and anxiety disorders has not been established. The dif-
ﬁculty of developing novel anxiolytic drugs is illustrated by the
fact that existing anxiolytic drugs such as benzodiazepines (BZs)
and selective serotonin (5-hydroxytryptamine, 5-HT) reuptake
inhibitors (SSRIs) have been developed several decades ago. The
development of BZs was the result of serendipity and SSRIs were
primarily developed to treat major depressive disorder. Interest-
ingly, when patients start using SSRIs they experience anxiogenic
effects of the drug, while after administration of several weeks
SSRIs work anxiolytically. This is probably due to activation of 5-
HT2C receptors as antagonists for these receptors are able to reverse
the acute anxiogenic effect of SSRIs (Bagdy et al., 2001). More-
over, chronic exposure to SSRIs has been shown to downregulate
5-HT2C receptors in the cortex (Attar-Levy et al., 1999). Although
extensive search has occurred in the ensuing decades to ﬁnd new
targets for anxiolytics based on the known and anticipated neuro-
chemical mechanisms underlying anxiety, no real breakthroughs
have emerged. Currently, SSRIs remain the preferred drugs for the
treatment of anxiety disorders (augmented with BZs for a limited
time interval). Although efﬁcacious, some patients are treatment
resistant, and inherent disadvantages with regard to side effects
are attached to the use of SSRIs and BZs. Therefore, preclinical
and clinical studies over the last decades have focused on other
mechanisms to target anxiety processes in order to ultimately treat
anxiety disorders. Since then, evidence has emerged for several
novel anxiety targets, including the corticotropin-releasing factor
1 (CRF1) receptors, neurokinin 1 (NK-1) receptors, and gluco-
corticoid receptors (for review, see Cryan and Sweeney, 2011).
Although the preclinical efﬁcacy of drugs targeting these neu-
rotransmitters was often encouraging during development, no
superior therapeutic anxiolytic effects have been found in sub-
sequent clinical trials. Thus, no novel anxiolytic drug targets have
reached the market to replace the current treatment choices. Sur-
prisingly, even though targets such as the serotonin 1A (5-HT1A)
receptor, serotonin 2 (5-HT2) receptor, the serotonin transporter
(5-HTT), and the gamma-aminobutyric acid-A (GABAA) recep-
tor have yielded drugs with known efﬁcacy, the relation between
the genetic background of these targets and anxiety symptoms and
disorders is little understood. The complexity of anxiety disorders
calls for a multidisciplinary approach of the phenomenon of anx-
iety. In this review, we argue that by using translational preclinical
models, anxiety-related genes can bemapped and this information
may subsequently be used to enhance our understanding of clin-
ical studies in order to identify novel drug targets for anxiety. To
this end, this review focuses on the convincing evidence stemming
frompreclinical and clinical studies that genes involved in the sero-
tonin and GABA system play a pivotal role in the development of
anxiety disorders. These 5-HTergic andGABAergic genes are high-
lighted throughout this review to illustrate the complexity of the
genetic background of anxiety disorders.
HERITABILITY OF ANXIETY DISORDERS
From family studies, the risk to develop an anxiety disorder
such as PD, phobias, OCD, or GAD is three- to sixfold higher
in ﬁrst-degree relatives of affected probands compared to unaf-
fected individuals (Chantarujikapong et al., 2001; Hettema et al.,
2001). Also, twin studies have aided in estimating the genetic
and environmental components of the variance in PTSD (See-
dat et al., 2001). Moreover, concordance rates in monozygotic
twins have been found to be increased compared to dizygotic
twins for anxiety disorders with an estimated heritability in the
range of 20–40% (Hettema et al., 2005). Thus, it is clear that
genetic variability contributes to a certain extent to the risk for
anxiety disorders. Nevertheless, the rather limited heritability
implies that anxiety disorders are not mere genetically deﬁned
disorders.
LINKAGE MAPPING
When a disease runs in the family, genetic markers in several gen-
erations can be studied, and such linkage mapping has been found
to be critical for identifying genes that are causal for anxiety disor-
ders. It is assumed that a gene contributing to a disease is located in
the same area of the genome as the geneticmarker. Signiﬁcant link-
age for anxiety and PD has been reported at chromosomes 9q31
(Thorgeirsson et al., 2003), 2q (Fyer et al., 2006), 7p (Knowles
et al., 1998), 13q (Hamilton et al., 2003), 15q (Fyer et al., 2006),
and 22q (Hamilton et al., 2003). Signiﬁcant linkages were also
found for a “PD syndrome” (13q; Weissman et al., 2000). Addi-
tionally, suggestive-linkage regions were reported for agoraphobia
(1q; Gelernter et al., 2001), PD and agoraphobia (12q; Smoller
et al., 2001a), social phobia (Gelernter et al., 2004), and markers
for speciﬁc phobia on chromosome 14 (Gelernter et al., 2003).
Finally, Kaabi et al. (2006) detected a strong linkage signal for
anxiety and PD on chromosome 4 (4q31-q34) at marker D4S413.
Linkage studies forOCDhave only revealed single nucleotide poly-
morphisms (SNPs) in the glutamate transporter gene SLC1A1 on
9p24 (Walitza et al., 2010). Although linkage studies have impli-
cated several chromosomal regions that may harbor susceptibility
genes (Smoller et al., 2008a), no candidate genes have emerged that
play a straightforward role in the expression for a vulnerability to
anxiety or anxiety disorders (Smoller et al., 2009). This is probably
due to the fact that several genetic risk factors only explain a lim-
ited amount of variance. Moreover, the strongest linkage signals
seem to derive from recessive and highly penetrant diseases. Link-
age studies are good to detect regions involved in these recessive
diseases and can narrow down the search for causal variants to a
few million base pairs.
ASSOCIATION MAPPING
Association studies compare allelic variation in a group of patients
to a healthy control population. When a certain allele plays a role
in the development or susceptibility of a disease or is correlated
with a causal allele, the frequency of this allele will be increased in
the case population compared to the control population. Usually,
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linkage studies result in a signal of candidate genes in a certain
region and are followed by a genetic association study on alle-
les in that genetic region. In this way, a speciﬁc gene or even a
speciﬁc allele can be identiﬁed to play a causal role in a certain
disorder. Genetic association studies have become the predomi-
nant method for identifying susceptibility loci for complex traits
(Smoller et al., 2008a). Several genes have been associated with
PD (Hovatta and Barlow, 2008), such as, e.g., catechol-o-methyl
transferase (COMT; Hamilton et al., 2002; Domschke et al., 2004;
Woo et al., 2004; Rothe et al., 2006), adenosine A2A receptor
(ADORA2A; Deckert et al., 1998; Hamilton et al., 2004), chole-
cystokinin (CCK; Wang et al., 1998; Hattori et al., 2001; Maron
et al., 2005),CCK-B receptor (Kennedy et al., 1999), 5-HT1A recep-
tor (HTR1A; Maron et al., 2004; Rothe et al., 2004; Fakra et al.,
2009; Choi et al., 2010), 5-HT2A receptor (HTR2A; Inada et al.,
2003; Maron et al., 2005), 5-HTT (SLC6A4; Lesch et al., 1996;
McDougle et al., 1998; Bengel et al., 1999; Ohara et al., 1999; Lee
et al., 2005; Munafo et al., 2005), monoamine oxidase A (MAO-A;
Deckert et al., 1999; Inada et al., 2003; Maron et al., 2004; Samo-
chowiec et al., 2004), and the regulator of G protein signaling
2 (Rgs2; Smoller et al., 2008b). Genetic association studies have
also revealed several genes involved in PTSD, with most attention
for genes involved in the hypothalamus–pituitary–adrenal (HPA)
axis and the regulation of neurobiological pathways such as the
SLC6A4, DAT1, DRD2, DRD4, FKBP5, and GCCR (systematically
reviewed in Digangi et al., 2013). Although linkage studies only
found SNPs in the SLC1A1 to be associated with OCD, association
studies have found more genes such as SLC6A4, HTR1D, HTR2A,
HTR2C, DRD4, DRD2, SLC1a1, GRIN2B, GABBR1, COMT,
MAO-A, TPH1, TPH2, BDNF (brain-derived neurotrophic fac-
tor), NTRK2, OLIG2, and MOG (reviewed in Walitza et al., 2010).
For GAD the Gad2, Rgs2, and Ppargc1a (in anxiety-spectrum
disorders) were found to be associated (Sokolowska and Hov-
atta, 2013). Moreover in general CDH2, ALAD, PSAP, EPB41L4A,
DYNLL2, and PTGDS that were associated with anxiety disor-
ders (Sokolowska and Hovatta, 2013). Among all these genes, the
SLC6A4 (5-HTT) is one of the most widely investigated genes in
relation to anxiety-related personality traits (Munafo et al., 2003).
Most association studies of anxiety disorder have focused on can-
didate genes, which are suspected to play a role in a particular
anxiety disorder. This can be based on earlier biological evi-
dence (biological candidate) or because these genes are located
within loci previously implicated via linkage studies (positional
candidates). However, most likely more than one gene variant is
involved in the regulation of distinct emotional responses, which
together with the environmental inﬂuence will determinewhowill
become affected. Studies in animal models of anxiety have pro-
vided evidence for the involvement of certain genes. The most
intensively studied candidate genes are related to neurotransmit-
ter systems implicated in the regulation of anxiety, to various
neuropeptides, and to stress-related genes, and for that reason
have functioned as targets to develop anxiolytic drugs. These
targets include 5-HT, noradrenalin (NE), glutamate, dopamine,
GABA, RGS2, and neuropeptides (CRF, neuropeptide Y, BDNF).
To address the complexity of psychiatric disorders, two strate-
gies have evolved; (1) going “big” and (2) going “deep” (Smoller
et al., 2009).
GENOME-WIDE ASSOCIATION STUDIES
First studies have looked for SNPs based on an unbiased survey
of the entire genome (genome-wide association studies, GWAS).
The main aim of this strategy is to increase the explained vari-
ance of genetic studies by increasing the number of genes and,
subsequently, sample size. By selecting a reduced set of SNPs that
adequately represents the genetic variation, the whole DNA can be
investigated with DNA chips measuring up to millions of SNPs.
Although statistically stringent demands are uphold, the GWAS
approach has resulted in the elucidation of genes and genetic
variants involved in complex diseases such as autism and bipo-
lar disorder although at a disappointing level (Chen et al., 2010;
Gershon et al., 2011). With regard to anxiety, several anxiety genes
have been found (Hovatta and Barlow, 2008), yet replication stud-
ies are lacking. Currently, GWAS are still on-going to localize and
identify putative risk genes for anxiety disorders. The reason why
GWAS were relatively unsuccessful for anxiety disorders is not
fully clear. Several causes have been proposed, to name a few:
(1) small effect sizes (Manolio et al., 2009); (2) new analytical
approaches are necessary to detect more locations in the genome
(Lubke et al., 2012); (3) epistasis, only a few genes together could
contribute to a genetic risk while a gene on its own will never be
identiﬁed. Network- and pathway-based methods are necessary
in identifying candidate genes and to provide functional links to
connect genetic variants to phenotypes (reviewed in Sun, 2012);
(4) copy number variations (CNVs) might be responsible for a
non-trivial proportion of common risk disease. The majority of
CNVs remain invisible to current GWAS technology and would
require whole-genome sequencing instead; (5) epigenetic inheri-
tance, all technologies that are used in GWAS are based on DNA
sequence, however not all inherited information is carried in the
DNA.Therefore,GWASarenot detecting epigenetic variations and
epigenome-wide association studies should be performed to dis-
cover epigenetically inherited variations; (6) gene × environment
(G × E) effects, as in many psychiatric disorders, the environment
induces complex G × E interactions which are hard to pick up by
GWAS technology.
ENDOPHENOTYPES
Instead of going big, another strategy that has been increasingly
applied is going “deep,” i.e., the use of endophenotypes or inter-
mediate phenotypes. These familiar or heritable traits are assumed
to underlie anxiety disorders and may result in more insight
into neurobiological mechanisms compared to classically deﬁned
anxiety disorder. Endophenotypes are particularly relevant in
anxiety disorders, as the neural circuitry and central pathways
mediating anxiety are relatively well known, partly because of
extensive animal models and knowledge derived from functional
magnetic resonance imaging (fMRI) studies in humans. Those
enable the study of the relationship between activities in particu-
lar brain areas and anxiety. The amygdala, a limbic area involved
in emotional processing, shows enhanced activity in phobias and
PTSD compared to healthy individuals (Etkin and Wager, 2007).
Such (endo) phenotypes are important targets for genetic stud-
ies because the link between genetic variation and disorder risk is
reﬂected more directly, as, e.g., became clear when speciﬁc candi-
date polymorphism were associated with such brain parameters.
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A polymorphism in the promoter of the 5-HTT gene has been
frequently associated with amygdala reactivity (Hariri et al., 2002;
Hariri and Holmes, 2006) implicating the S-allele (low transcrip-
tional activity of the 5-HTT) in the increased amygdala reactivity
toward external stimuli (Hariri, 2009). Anxiety and related stress
responses are conserved in mammals at different levels. Therefore,
similar genes in humans and rodents may regulate critical aspects
of anxiety.While in humans it is difﬁcult to control the genetic het-
erogeneity and environmental inﬂuences, animal models provide
the possibility to identify novel candidate genes under controlled
circumstances. In the section “preclinical genetic approaches to
anxiety”, we describe some animal models of anxiety that made it
possible to study in vivo genetic associations at a functional level.
CONCLUSION
In conclusion, genetic studies aiming to unravel the neurobiologi-
cal background of anxiety disorders have proven to be challenging.
This is likely due to a complex and polygenic genetic background
of anxiety disorders in which many genes inﬂuence the risk to
develop anxiety disorders, each of them with a small effect. More-
over, epistatic processes, having the ability to mask the phenotype
derived fromother genes, are also very likely to be involvedwhereas
environmental factors induce complex G × E interactions. The
fact that different susceptibility genes segregate in different fam-
ilies possibly plays a role, making it extremely difﬁcult to detect
relatively small and diverse effects. Reported genes that have been
associated with anxiety disorders have often been followed by
non-replications. The risk of false positives is considerable and
meta-analysis studies are needed to hint at a putative suscepti-
bility gene or deﬁnitively reject it. Even if replications have been
found, the number of negative studies often exceeds the number of
positive studies (Smoller et al., 2009). These challenges have led to
a generally critical perspective in the search of mental illness genes
(Muglia, 2011; Klein et al., 2012). Moreover, Crow (2011) critically
questions why only 1–2% of the 80–90% heritability of major psy-
chiatric diseases can be attributed to genes identiﬁed by linkage
and association. This suggests that many loci with small effects are
involved for the heritability of anxiety-related personality traits
(Shifman et al., 2008).
PRECLINICAL GENETIC APPROACHES TO ANXIETY
Despite extensive research, human linkage and association studies
have not led to major breakthroughs so far. Therefore, it is of great
importance to use other approaches in studying the involvement
of genes in anxiety disorders as well. Animal pathology resembles
human pathology to a certain (but varying) degree (Fernando and
Robbins, 2011) and has greatly enhanced our knowledge in the
neurobiological mechanisms underlying anxiety. Animal models
canbepowerful in dissecting putative genes in anxiety and anxiety-
associated traits (Flint and Shifman, 2008; Kas et al., 2011), which
can be used in parallel to human genetic studies. Because genomic
technology advances rapidly, linkage between targets and neu-
ronal circuitry and genetic factors involved in anxiety disorders are
becoming increasingly elucidated. Fundamental research aimed at
these targetsmay contribute to unraveling novel insights in anxiety
processes and consequently engender new opportunities for drug
discovery. The future needs a strict translational approach; data
found in human (anxiety) research including genetic and environ-
mental factors, should be used to formulate scientiﬁc approaches
in animals and vice versa. In animals, we have the opportunity
to apply cell-speciﬁc inducible knock-outs or knock-ins. More-
over, new optogenetic technology enables selective manipulation
of cellular mechanisms and circuit functions linked to the gene’s
suggested function (Tye andDeisseroth, 2012). The 5-HT1A recep-
tor, the 5-HT2 receptor, the 5-HTT, and the GABAA receptor
complex belong to the most known and discussed targets in the
ﬁeld and will therefore be discussed below. Human and animal
research continues to ﬁnd new mechanisms around these targets
and involvement of these targets in neural networks involved in
anxiety modulation, opening new possibilities to apply in animal
models and human psychopathology.
ANIMAL MODELS OF ANXIETY
The development of predictive animal models and genetically
modiﬁed rodents has aided to clarify the role of several pharma-
cological molecules in brain circuits relevant to anxiety processes,
including normal and abnormal behavior. Many animal models
for anxiety are based on the natural behavior patterns of rodents
(Rodgers et al., 1997). These ethologically based behavioral mod-
els include “approach-avoidance” tasks (Cryan and Holmes, 2005)
where animals are exposed to aversive environments such as an
open ﬁeld, elevated plus maze or light/dark box and avoid the
aversive arena (center of open ﬁeld, open arms of elevated plus
maze, light arena in light/dark box). Besides these unconditioned
procedures also conditioned procedures have been used to model
anxiety disorders, including conﬂict procedures such as the Vogel
water-lick conﬂict test (Vogel et al., 1971), defensive burying tests
(de Boer and Koolhaas, 2003), the four-plate test (Boissier et al.,
1968), and fear-potentiated startle (Brown et al., 1951). Next to
these tests also other parameters have been developed to assess
anxiety such as the use of radiotelemetry to assess physiological
parameters (Bouwknecht et al., 2007), social interaction tests (File
and Seth, 2003), predator stress (Blanchard and Blanchard, 1971),
and stress-induced vocalizations (Sanchez, 2003). All these mod-
els assess behavior that is functionally related to human anxiety as
they show good face and construct validity.
THE 5-HT1A RECEPTOR
The 5-HT1A receptor has been implied in anxiety because 5-HT1A
receptor agonists exert anxiolytic activity in rodent models of anx-
iety (Olivier et al., 1999). Although clinically, development of new
5-HT1A receptor agonists for anxiety disorders (e.g., ipsapirone,
gepirone, tandospirone, ﬂesinoxan) failed, the 5-HT1A receptor
has received considerable interest as a critical target implied in
anxiety (Olivier et al., 1999; Holmes, 2008; Lanfumey et al., 2008;
Akimova et al., 2009; Savitz et al., 2009). 5-HT1A receptors are
G protein-coupled inhibitory receptors expressed in 5-HTergic
neurons as autoreceptors and in non-5-HTergic neurons as het-
eroreceptors. The somatodendritic 5-HT1A autoreceptor controls
5-HTergic tone via feedback inhibition, although recently it was
shown that not all 5-HT neurons express the somatodendritic
5-HT1A autoreceptor mRNA (Kiyasova et al., 2013). It has been
hypothesized that desensitized 5-HT1A autoreceptors delay the
onset of action of SSRIs that act by enhancing brain 5-HT levels
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(Gardier et al., 1996; Blier et al., 1998). 5-HT1A receptors are quite
abundantly, although restrictedly present in some brain areas.
Autoreceptors are mainly, if not only, found in the dorsal and
median raphé nuclei, whereas postsynaptic heteroreceptors are
found in high densities in limbic regions (including hippocampus)
and in the frontal medial prefrontal and entorhinal cortices.
Human data
Genetic and imaging studies inhumans suggest that 5-HT1A recep-
tor density or regulation are associated with anxiety, but also
with the response to antidepressants (Lesch and Gutknecht, 2004).
An association was found between a C(-1019)G polymorphism
(rs6295G/C) in the promoter region of the 5-HT1A receptor gene
(Htr1a) andmood-related variables, including amygdala reactivity
(Fakra et al., 2009). The G-allele is associated with enhanced raphé
(presynaptic) 5-HT1A autoreceptor expression but reduced post-
synaptic 5-HT1A heteroreceptor expression (Le FranÇois et al.,
2008). How such changes contribute to an anxious phenotype is
not known yet. More polymorphisms in the Htr1a gene exist, but
it is not clear whether they inﬂuence anxiety (Drago et al., 2008).
Preclinical data
5-HT1A receptors were found to modulate anxiety. All generated
5-HT1A receptor knock-out (5-HT1A−/−) mice in several strains
displayed enhanced anxiety (Heisler et al., 1998; Parks et al., 1998;
Ramboz et al., 1998), although the anxious phenotype was depen-
dent on the paradigm used (Pattij et al., 2001). Interestingly, the
Swiss-Webster 5-HT1A−/− mouse displayed a reduced sensitivity
to the anxiolytic and sedative effects of diazepam, a non-α-subunit
selective GABAA-positive allosteric modulator (Sibille et al., 2000;
Olivier et al., 2001), indicating changes in some α-subunits of
the GABAA–BZ receptor complex. However, this BZ insensitiv-
ity did not occur in other strains (Olivier et al., 2001; Pattij et al.,
2002). Apparently, dysfunction of the GABAA–BZ system is not
a prerequisite for the “anxiogenic” phenotype of the 5-HT1A−/−
mouse. The anxiogenic phenotype in the 5-HT1A−/− mouse was
not responding to SSRIs (Santarelli et al., 2003), although Guil-
loux et al. (2006) showed that 5-HT1A−/− mice on a C57Bl/6
background did respond better to SSRIs compared to wildtypes.
Moreover, it appeared that overexpression of the 5-HT1A recep-
tor reduced anxiety (Kusserow et al., 2004). Rescue experiments
of forebrain 5-HT1A receptors showed that postsynaptic 5-HT1A
receptors are critical in the development of the anxiogenic phe-
notype in the null mutations (Gross et al., 2002). In addition,
transgenic developmental overexpression of 5-HT1A receptors in
the rostral brain was sufﬁcient to restore normal anxiety levels.
Pharmacological blockade of 5-HT1A receptors in early devel-
opment, but not in adulthood, appeared sufﬁcient to enhance
anxious behavior in wildtype mice (Lo Iacono and Gross, 2008;
Vinkers et al., 2010a). Zanettini et al. (2010) found increased social
anxiety in the 5-HT1A−/− mice, however thiswas reversedbypost-
natal handling, indicating that neural circuits involved with social
anxiety are susceptible to early-life experiences. The complex reg-
ulation of anxiety processes during development and adulthood
illustrates the complexity of the neural substrate. Also the genetic
regulation of anxiety and its pathology makes it clear that straight-
forward and simple relationships between the function of a certain
receptor and anxiety are not very likely. Richardson-Jones et al.
(2010) were able to manipulate the level of presynaptic 5-HT1A
autoreceptors during adulthood without a concomitant change
in postsynaptic 5-HT1A heteroreceptors. Mice with higher (1A-
high) or lower (1A-low) autoreceptor levels were tested on their
stress vulnerability and response to antidepressants. 1A-low mice
showed enhanced 5-HT tone and still respond to an SSRI, whereas
1A-high mice had decreased 5-HT tone and were unresponsive
to SSRIs. The authors suggest that 1A-lows reﬂect human C/C,
whereas 1A-highs model G/G carriers of the Htr1a C(-1019)G
polymorphism. Such genetic mouse models are extremely useful
in studying the underlying processes emerging in anxiety disor-
ders. In addition, Bortolozzi et al. (2012) showed that C-1A-siRNA
can be used in vivo to selectively silence the 5-HT1A autorecep-
tor resulting in reduced 5-HT1A-autoreceptor expression, but no
alterations in postsynaptic 5-HT1A receptors. Interestingly C-1A-
siRNA increased the SSRI-induce elevation of extracellular 5-HT.
Effects were seen after i.c.v. and intranasal C-1A-siRNA infusion
which opens up new possible therapeutic applications. In conclu-
sion, by genetic manipulation it was possible to study the exact
role of speciﬁc 5-HT1A receptors (e.g., presynaptic autoreceptors
and postsynaptic heteroreceptors) in anxious behavior. Rodents
can be manipulated in one speciﬁc gene, or even in a speciﬁc area.
By doing so, the involvement of different 5-HT1A receptors within
anxiety disorders can be unraveled, and anxiolytic drugs can be
developed for more speciﬁc targets (e.g., targeting only postsynap-
tical 5-HT1A receptors in the rostral brain). Moreover, changes in
other mechanisms in the brain in the modiﬁed mutant mouse
can direct us to putative other and relevant targets and mecha-
nisms involved in the complex anxiety phenotypes emerging. For
example Pet1, a transcriptional factor of the ETS (E-twenty six)
family, is important for determining the identity of 5-HT neurons
in the raphe. Kiyasova et al. (2011) investigated 5-HT neurons in
the Pet 1 knock-out mice and discovered a subset of 5-HT neurons
that were either Pet1-dependent or Pet1-resistant, which resulted
in different morphological features. Moreover, Pet1 knock-out
mice showed reduced anxiety-like behavior in conﬂict-tests, but
increased fear in aversive conditioning paradigms. Thus, Pet1 plays
an important role in the acquisition and maintenance of 5-HT
identity (Gaspar and Lillesaar, 2012; Andrade and Haj-Dahmane,
2013). These ﬁndings suggest that the differentiation of subpopu-
lations of 5-HT neurons could also be a factor contributing to the
development of anxiety disorders.
5-HT2 RECEPTORS
Clinical data
The 5-HT2 receptor subtypes are implicated in anxiety and in the
mechanismsof related treatments (Quesseveur et al., 2012). 5-HT2
receptors couple to multiple cellular signaling pathways and are
involved in several physiological brain functions (Leysen, 2004).
For example, when SSRIs are combined with 5-HT2C receptor
antagonists this may result in greater efﬁcacy in reducing anxiety
symptoms and improving sleep (Garner et al., 2009). Agomelatine
is a melatonergic receptor (M1 and M2) agonist, but also contains
5-HT2C receptor antagonistic properties, and has anxiolytic prop-
erties in patients with GAD (Stein et al., 2008). However, the initial
promise for 5-HT2C antagonists such as deramciclane in GAD
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(Naukkarinen et al., 2005) has still to be conﬁrmed consistently
within large randomized placebo controlled studies.
Preclinical data
As in patients with GAD, agomelatine has been shown to relieve
anxiety-like behavior in animals (Millan et al., 2005). More-
over, the 5-HT2C receptor antagonist SB242084 increased the
response of SSRIs in animal models (Cremers et al., 2004).
Interestingly, Gomes and Nunes-de-Souza (2009) showed that
stimulation of 5-HT2A/2C receptors rather than stimulation of 5-
HT1A receptors in the periaqueductal gray matter (PAG) attenuate
anxiety-like behaviors in mice previously exposed to the elevated
plus maze. Moreover, in mice intra-PAG infusions of mCPP
(meta-chlorophenylpiperazine), a 5-HT2B/2C receptor agonist,
attenuated anxiety-like behavior in the elevated plus maze which
was blocked by the 5-HT2A/2C receptor antagonist ketanserin
(Nunes-de-Souza et al., 2008). Thus 5-HT2A/2C receptors within
the PAG play a key role in the regulation of anxiety-like behav-
ior in mice. With respect to interactions of the 5-HT2 receptor
it was shown that CRF sensitized the 5-HT2 receptor-mediated
signaling through the CRF1 receptor. This resulted into increased
anxiety-like behavior in mice (Magalhaes et al., 2010), indicating a
functional interaction between CRF and 5-HT. Furthermore, eti-
foxine, aGABAA receptor potentiator, dose-dependently increased
the number of punished crossing in a four-plate test in mice
(decreased anxiety). Interestingly this anti-punishment effect was
blocked when a 5-HT2A antagonist was administered (Bourin
and Hascoet, 2010). In addition co-administration of the 5-HT2A
receptor agonist DOI together with a subthreshold dose of eti-
foxine induced an anti-punishment effect as well. Together these
data indicate that the effect of etifoxine was modulated by 5-HT2A
ligands and that GABA and 5-HT can be co-released and act as
co-transmitters in some regions of the central nervous system
(CNS; Bourin and Hascoet, 2010). Several studies have suggested
that 5-HT2A receptors modulate learning and memory (Meneses,
2007a,b). As such, Zhang et al. (2013) found that stimulation of
5-HT2A receptors with the agonist TCB-2 enhanced the extinction
of cued fear memory in mice after trace and delay fear condi-
tioning paradigms, while blockage with MDL 11,939 showed the
opposite effect. With respect to G × E interaction it was shown
that maternal separation increased adult anxiety behavior (Huot
et al., 2001; Kalinichev et al., 2002). Interestingly, Benekareddy
et al. (2011) have shown that blockade of the 5-HT2 receptor
(ketanserin) during early postnatal life prevented the increased
anxiety seen in animals exposed tomaternal separation. Moreover,
the enhanced 5-HT2A receptor mRNA in the prefrontal cortex
was also blocked by postnatal treatment of ketanserin, implicat-
ing that the 5-HT2 receptors are involved in the adverse effects
of maternal separation. In addition to the pharmacological stim-
ulation and blockage of the 5-HT2 receptor, disruption of the
5-HT2A receptor in mice increased anxiety-like behavior in con-
ﬂict anxiety paradigms as well (Weisstaub et al., 2006). Martin
et al. (2013) created amousemodel expressing only the fully edited
VGV isoform of the 5-HT2C receptor and showed that these mice
had increased anxiety-like behavior after stimulation with a 5-
HT2C receptor agonist in the social interaction test. Moreover, in
response to an innately aversive ultrasonic stimulus these mice
freezed signiﬁcantly more and displayed decreased brain 5-HT
turnover during stress.When these resultswere put in relationwith
the 5-HT2C receptor mRNA splicing process it turned out that the
truncated protein (5-HT2C receptor-Tr) interacted with the full-
length receptor (5-HT2C receptor-Fl). The 5-HT2C receptor-Tr
was localized in the endoplasmic reticulum where it bound to the
5-HT2C receptor-Fl. As a result, the 5-HT2C receptor-Fl could not
reach the plasma membrane (Martin et al., 2013). These results
show that the 5-HT2C receptor pre-mRNA editing and splicing
altering 5-HT2C receptor levels are involved in pathological con-
ditions. Finally, the decreased sociability and snifﬁng induced by
mCPP (5-HT2B/2C agonist) in 5-HTT+/+ mice, was not seen in
5-HTT−/− mice (Moya et al., 2011) which is probably due to
increases in RNA editing of the 5-HT2C receptor in the amygdala
of 5-HTT−/− mice that generates less active reporter isoforms.
In conclusion, the 5-HT2 receptors are involved in anxiety pro-
cesses; however more research is needed to further dissect the
physiological relevance in different brain regions.
THE SEROTONIN TRANSPORTER (5-HTT)
Human data
The 5-HTT has been implied in processes underlying mood, anx-
iety and associate disorders mainly because SSRI anxiolytics block
5-HTuptake into the neuron thereby increasing 5-HTergic output.
Polymorphisms in the promoter of the 5-HTT gene (5-HTTPRL)
and its associated transcriptional control region, inﬂuence the
functioning of the 5-HTergic system (Lesch, 2001). Variable num-
bers of tandem repeat polymorphisms are known in intron 2 as
well as several SNPs that inﬂuence the structure of the 5-HTT
protein (Murphy and Lesch, 2008). This makes the modulation of
5-HTergic transmission via the 5-HTT mechanism highly com-
plex and gives probably an important insight in the factors that
play a role in the genetic complexity of any psychiatric disorder.
Gene variations inﬂuence intermediate biological phenotypes in
concert with other genes, epigenetic variation, environmental and
developmental factors. All these complex interactions contribute
to the risk or resilience to develop a psychiatric condition. One
avenue to pursue would be to try to ﬁnd associations between
speciﬁc candidate genes and intermediate phenotypes mediat-
ing between a moderating allele and a more complex disease
phenotype (Murrough and Charney, 2011).
The 5-HTTLPR allele variations are called the short “S” allele
and the long“L” allele. The S-allele has 44 base pairs less and lower
transcriptional activity of the 5-HTT gene than the L-form. The
S-allele has been the focus of many association studies (Hamilton,
2009). Although negative studies and non-replications with anxi-
ety phenotypes have been reported (e.g., Risch et al., 2009; Grabe
et al., 2011),many reported associations with anxiety-related traits
and anxiety disorders (Lesch et al., 1996; McDougle et al., 1998;
Bengel et al., 1999; Ohara et al., 1999; van Gestel et al., 2002; Lee
et al., 2005; Munafo et al., 2005). Considerable evidence showed
that after stressful life-events the low expression S-allele is associ-
ated with poorer outcomes (Lesch et al., 1996; Caspi et al., 2003). A
signiﬁcant interaction between maternal anxiety during gestation
and subsequent levels of infant negative emotionality at 6 months
of age was modulated by the 5-HTTLPR of the child (Pluess et al.,
2011). Moreover, SS-allele carriers appeared particularly sensitive
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toward unpredictability as seen by modulated attention to the
stress (Drabant et al., 2012), suggesting that such a mechanism
may underlie the risk for psychopathology. In addition, deduc-
tive reasoning appeared also dependent on 5-HTTPRL genotype.
Differences in 5-HTT functioning renders some individuals more
vulnerable to emotional factors, thereby generating a deleterious
effect on rational reasoning (Stollstorff et al., 2013). A gene × gene
interaction was found between the 5-HTTLPR (measure in LL-
variants) and an oxytocin receptor variant (TT variant of the
SNP rs2268498) on individual differences in negative emotionality
(Montag et al., 2011). Such data indicate that 5-HTergic and oxy-
tocinergic neurotransmission processes are somewhere entwined
and seem to play a role in affective disorders. In general, S-alleles
of the 5-HTTLPR are associated with increased risk for a vari-
ety of psychiatric disorders, including anxiety. Thus, the S-allele
is considered a “risk” or “vulnerability” allele (Caspi et al., 2010)
whereas the function of the L-allele is far less clear although this
allele has been suggested as a potential risk factor for the devel-
opment of psychopathic traits too (Glenn, 2011). Because every
human has either L, S or both alleles and most people do not suf-
fer from psychiatric abnormalities; it must be assumed that the
genome includes several “protective” alleles that make many indi-
viduals resilient to stress and pathology. Such protective genes have
been suggested, e.g., the CRF1-receptor variants that have been
associated with protection from the extreme stresses of maltreat-
ment during childhood (Polanczyk et al., 2009) and protective,
emotional-resilience enhancing effects of the L-allele in students
(Stein et al., 2009). Belsky et al. (2009) suggested that S-allele car-
riers are more vulnerable in general, not only negatively, but also
positively. Thus“vulnerability genes”or“risk alleles” seem to make
individuals more susceptible to environmental inﬂuences, for bet-
ter and for worse. Homberg and Lesch (2011) take the hypothesis
that S-carriers perform better in cognitive tasks than L-carriers
and argue for a switch from a deﬁcit-orientated connotation of the
5-HTTLPR variants to a cognitive superiority of S-allele carriers
(which have enhanced reactivity of corticolimbic neural circuitry).
Environmental conditions will determine whether a positive (cog-
nitive) or negative (emotional) response will happen. Also Hankin
et al. (2011) showed that SS-allele children were more sensitive
to the environment. Under unsupportive, non-positive parenting
SS-allele children exhibit low levels of positive affect, but with
supportive/positive parenting these children displayed higher lev-
els of positive affect. In addition to this, Eley et al. (2012) showed
an association between the 5-HTTLPR and response to psycho-
logical treatment. That is, SS-allele children with anxiety disorder
respond up to 20% better to psychotherapy compared to L-allele
(SL/LL) carriers. This environmental sensitivity of the 5-HTTLPR
makes it even more difﬁcult, and should be taken into account
when treating anxiety disorders.
Preclinical data
Several animal models were created to study the role of the 5-
HTT and altered 5-HT signaling in the in vivo actions of SSRIs.
For instance, Thompson et al. (2011) created a knock-in mouse
expressing 5-HTTM172,which did not affect the recognition of 5-
HT, but affected the serotonergic system and emotional behavior.
Also, mice overexpressing 5-HTT have been generated resulting in
reduced anxiety levels and bodyweight (Jennings et al., 2006; Line
et al., 2011) and enhanced 5-HT2A/C receptor function (Dawson
et al., 2011). This model, together with 5-HTT knock-out (5-
HTT−/−) models might eliminate the effects of lifelong 5-HTT
disturbances with all the compensatory effects occurring over the
life span. Both 5-HTT−/− mouse (Bengel et al., 1998) and rat
(Smits et al., 2006) have been created. 5-HTT−/− rodents dis-
play increased extracellular 5-HT in several brain regions (Fabre
et al., 2000; Mathews et al., 2004; Shen et al., 2004; Homberg et al.,
2007a; Olivier et al., 2008). Due to these increased extracellular
5-HT levels alterations in neurodevelopment and 5-HT synthe-
sis/metabolism are found (reviewed in Murphy and Lesch, 2008;
Homberg et al., 2010). 5-HTT−/− rodents have been considered as
an extreme model of the 5-HTTLPR polymorphisms in humans,
as brain and behavioral phenotypes of 5-HTT−/− animals resem-
ble the heterogeneity observed for the 5-HTTLPR (Hariri and
Holmes, 2006;Wellman et al., 2007; Homberg et al., 2008b; Olivier
et al., 2008).5-HTT−/− animals have an altered ability to cope
with stress and display anxiogenic and depressogenic behavior
(Holmes et al., 2002; Tjurmina et al., 2002; Adamec et al., 2006;
Wellman et al., 2007; Olivier et al., 2008; Jansen et al., 2010; Kalu-
eff et al., 2010). Interestingly, when the environment is rewarding,
5-HTT−/− rodents are more hypersensitive as shown by their
increased sensitivity for psychostimulants (Sora et al., 1998, 2001;
Homberg et al., 2008a; Nonkes et al., 2013) indicating that 5-
HTT−/− rodents are more sensitive to the environment. As found
in S-allele carriers (Roiser et al., 2006a,b, 2007; Finger et al., 2007),
improved cognition has been observed in 5-HTT−/− rodents
(Homberg et al., 2007b, 2008b; Brigman et al., 2010) together with
improved behavioral ﬂexibility, directing their behavior toward
the most rewarding stimuli (Brigman et al., 2010; Nonkes et al.,
2013). Reduced conditioned freezing to a predicted foot shock is
found in 5-HTT−/− rodents when a positive stimulus was given
(Nonkes et al., 2012). However, it appears that phenotypical plas-
ticity is not only present in 5-HTT−/− animals early in life, but
also later in life (Homberg and van den Hove, 2012). This also
accounts for heterozygous (5-HTT+/−) rodents, which might be
considered as a more valuable model for the 5-HTTLPR model
as they have reduced expression of the 5-HTT, comparable to
the S-allele carriers. For instance, low maternal care increased
anxiety-like behavior in adult 5-HTT+/− mice, but not in wild-
type littermates (Carola et al., 2008). This increased emotionality
was linked to increased BDNF mRNA levels in the hippocam-
pus, suggesting a role for BDNF in programing the 5-HTT+/−
brain to become more susceptible to the environment. Inter-
estingly, only 5-HTT+/− mice that experienced high maternal
care showed increased 5-HT and norepinephrine levels in the
hippocampus, together with decreased 5-HT turnover (Carola
et al., 2011). At baseline level, 5-HTT+/− mice display decreased
emotional behavior, however, upon prenatal maternal restraint
stress, 5-HTT+/− offspring displayed increased emotional behav-
ior (Van den Hove et al., 2011), although also decreased anxiety
levels and enhanced memory performance were found in these
mice. This is an important ﬁnding as individuals with anxiety
symptoms have a range of biases in emotion processing, such as
a willingness to selectively attend to thread cues (Bar-Haim et al.,
2007; Waters et al., 2008) and to interpret emotionally ambiguous
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stimuli in a negative manner (Mathews and MacLeod, 2005).
When 5-HTT−/− and 5-HTT+/− mice underwent a loser expe-
rience in a social defeat test they displayed delayed fear extinction
and decreased recall of extinction to a higher extent than wild-
types (Narayanan et al., 2011). In addition, 5-HTT−/− losers
displayed increased anxiety levels and reduced exploration (Jansen
et al., 2010). Similarly, increased escape latencies were found in
5-HTT−/− and 5-HTT+/− mice after repeated inescapable foot-
shock stress (Muller et al., 2011). Moreover, chronic psychosocial
stress due to an intruder in the cage resulted into decreased loco-
motor activity and increased social avoidance (Bartolomucci et al.,
2010). It is clear that both the immature developing brain as well
as the mature brain is sensitive to changes in the environment.
The advantage of having animal models for human disorders
is that underlying mechanisms in the brain can be more eas-
ily studied as environmental inﬂuences can be regulated. With
use of for example fMRI or microPET (micro-positron emission
tomography) scanning, brain areas can be studied in humans.
By doing so, it was discovered that the amygdala and prefrontal
cortex of S-allele carriers showed hyperactivity upon environ-
mental stimuli (Hariri et al., 2002; Kalin et al., 2008). However,
a molecular understanding of this phenomenon is lacking, while
such understanding might be helpful in identifying new targets for
the diagnoses and therapy of anxiety disorders. With use of ani-
mal models it is possible to study the gene, the environment and
their interactions. For example, low maternal care caused deﬁ-
cient GABAA receptor binding in the amygdala during adulthood.
In pups with low maternal care increased α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid receptor binding was found in
the hippocampus, which correlated with BDNF mRNA levels in
the somatosensory cortex. These effects are independent of geno-
type, and are only environmental. However, lower maternal care
in 5-HTT−/− mice elevated BDNFmRNA levels in the hippocam-
pus. Moreover, it was shown that loser stress in a resident-intruder
test increased pronounced neuroplastic changes of pyramidal neu-
rons in the prelimbic cortex and amygdala (Nietzer et al., 2011).
Also effects on the corticolimbic system were found (reviewed in
Homberg and van den Hove, 2012). While we now only discussed
the G × E interactions, epigenetics is probably also a key contrib-
utor for these interactions. The relationship between genetic and
epigenetic variation at the 5-HTT gene has so far not been studied
in 5-HTT-deﬁcient animal models. But 5-HTT-deﬁcient rodents
may be particularly suitable to study these interactions.
GABAA RECEPTOR α SUBUNITS AND ANXIETY
In the 1950s, BZs were serendipitously found as having therapeu-
tically interesting activity with anxiolysis, sedation, anticonvulsive
activity, and muscle relaxation. The molecular target of BZs is the
GABAA receptor (Möhler and Okada, 1977). BZs mediate their
actions via a modulatory binding site that is present on most, but
not all GABAA receptors. The binding site for BZs is formed by one
of the α subunits (α1, α2, α3, or α5) and a γ subunit (almost exclu-
sively the γ2 subunit) GABAA receptors are the main inhibitory
neurons in the CNS and it is estimated that 20–30% of all neu-
rons in the CNS are of the GABAA type. BZs do not open the Cl−
channel in the absence of GABA. Only if the GABA receptor site is
activated, activation of the BZ site may modulate the opening of
the channel. Ligands at the BZ binding site are allosteric modula-
tors. They modify the efﬁcacy and/or afﬁnity of GABA in positive
(positive allostericmodulation, PAM),negative (negative allosteric
modulation, NAM), or have neutral effects by stabilizing different
three-dimensional conformations of the complex. Selectivity of a
ligand for a speciﬁc receptor subtype can be obtained by afﬁnity
and/or by efﬁcacy changes that determine the potential potency of
a ligand.
Human data
Even though speciﬁc SNPs of the GABAergic system have been
found to play a role in anxiety disorders (Nemeroff, 2003; Kalu-
eff and Nutt, 2007), GWAS on anxiety disorders are scarce and
GABAergic candidate genes emerging from the existing studies
have been equivocal (Logue et al., 2012; Otowa et al., 2012). A lim-
ited number of studies suggested some link between the GABRA2
gene and anxiety. Nelson et al. (2009) found that polymorphisms
in the GABRA2 gene interact with early childhood trauma and
increase the risk for PTSD. Pham et al. (2009) found, investigat-
ing 26 SNPs in four GABAA receptor genes (GABRA2,3,6 and
GABRG2) that none of the allelic variation in these genes was
involved in liability to anxiety-spectrum disorders. Besides the
GABRA subunit genes, several otherGABAergic systems have been
implicated in the genetic load of GABA system pathways on the
psychobiology of anxiety. Suggestive signals for an associationwith
anxiety disorders and anxiety-related personality traits have been
found for other genes, e.g., glutamic acid decarboxylase 1 (Het-
tema et al., 2006) and 2 (Smoller et al., 2001b), b3 subunits of
the GABAA receptor (Feusner et al., 2001), the diazepam bind-
ing inhibitor (Thoeringer et al., 2007), and the GABA transporter
1 (Thoeringer et al., 2009). The latter authors suggest a multiple
system hit-theory in the genetic basis of anxiety disorders; many
loci at different genes of the GABA system, each with a small effect,
contribute to an individual’s risk on anxiety disorder. If several risk
genes are present, anxiety might develop depending upon adverse
environmental (stress) factors.
Preclinical data
By making the GABA α subunits insensitive to the diazepam
binding [α1(H101R) mice] strong evidence was gathered that α1
subunits were involved in sedative and anterograde amnesia effects
of diazepam. As such α2 point mutations [α2(H101R) mice] led to
absence of the anxiolytic and diminished muscle relaxant action,
but intact anxiolysis. Point mutations in α3 [α3(H126R) mice]
and α5 [α5(105R) mice] did not diazepam-induced myorelax-
ation, whereas sedation and anxiolysis were intact. Such data
strongly suggest a functional differentiation in the GABAA recep-
tors depending on the α-subunit composition (for review, see
Möhler, 2006; Rudolph and Knoﬂach, 2011). Classic BZs are
still frequently prescribed, have therapeutic activity but, inherent
to the activation of all relevant α-subunits, come with build-in
side effects. If used as anxiolytic tool, sedation is one of the
troubling side effects. Furthermore, upon chronic use, BZs can
lead to dependency, tolerance and induce abuse liability limit-
ing long-term use (Tan et al., 2011). Recent efforts have tried to
synthesize new drugs that have selectivity and potency for spe-
ciﬁc α subunits (Rudolph and Knoﬂach, 2011) although relatively
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selective drugs for the α1 subunit are already in use for seda-
tion/hypnotic purposes (zolpidem, zopiclone, (S)-zopiclone, and
zaleplon). Compounds that selectively activate theα2 subunits and
have no effects on any other α subunit might constitute an ideal,
non-sedative anxiolytic, although activation of α3 subunits might
contribute to an anxiolytic proﬁle (Dias et al., 2005; Vinkers et al.,
2009; Atack, 2010). L-838417, a partial PAM at α2, α3, and α5
containing GABAA receptors and an antagonist at α1 containing
receptors has a non-sedating anxiolytic proﬁle in mice (McKernan
et al., 2000; van Bogaert et al., 2006) and primates (Rowlett et al.,
2005). Development of this compound has been stopped due to an
unfavorable pharmacokinetic proﬁle (Scott-Stevens et al., 2005).
TPA023, an α2/α3 PAM, has anxiolytic and no sedative effects in
rodents (Atack et al., 2006). TPA023 was evaluated in three phase 2
studies in GAD and showed preliminary indications of anxiolytic
activity without sedation (Atack, 2010). However, this compound
had to be withdrawn due to severe preclinical toxicity. A compa-
rable story holds for ocinaplon, having a non-sedative anxiolytic
proﬁle in humans but also had to be withdrawn due to hepa-
totoxicity (Lippa et al., 2005; Czobor et al., 2010). Several other
ligands have been synthetized and tested, mostly restricted to pre-
clinical phases. It appears possible to make compounds with some
selectivity for speciﬁc α subunits but in vivo efﬁcacy is extremely
difﬁcult to design: both positive and negative allosteric modula-
tors have been found, sometimes even mixed PAM/NAM effects
on different α subunits are present or no selectivity is present
in vitro whereas in vivo some efﬁcacy is found (e.g., ocinaplon).
MRK-409, an extremely low partial agonist (PAM) at α1, α2, and
α5 containing GABAA receptors but higher intrinsic activity at
α3 subunit GABAA receptors, appeared to be anxioselective in
animals but sedative in humans, already at low (<10%) recep-
tor occupancy (Atack et al., 2011). One of the unresolved issues
around subunit selective GABAergic compounds is the issue of
tolerance and abuse potential. Does activation of all α subunit
containing GABAA receptors lead to addiction or is that caused
by speciﬁc α subunits? This is an important issue because the
development of potentially abusive medications will meet severe
constraints if not impossible. There is some evidence that acti-
vation of α1 subunits is essential in the addictive properties of
BZs (Tan et al., 2010, 2011). However, the processes of tolerance
development are complex and endpoint-dependent (Vinkers et al.,
2012). If the therapeutic effects of activation of α1-containing
GABAA receptors cannot be separated from potential addictive
side effects, no further development of α1 subunit speciﬁc ligands
can be expected. However, if addictive properties are not entwined
in (chronic) activation of the other α(2,3,5) subunits, new devel-
opments in the ﬁeld of anxiety (and others like cognition and
analgesia) might be expected (Mirza and Munro, 2010; Vinkers
et al., 2010a).
THE INTERACTION BETWEEN 5-HT AND GABA
The GABA and the serotonergic system may directly interact
(Lista et al., 1989; Gao et al., 1993; Fernandez-Guasti and Lopez-
Rubalcava, 1998). However, the evidence is equivocal (Shephard
et al., 1982; Thiebot, 1986). A serotonergic component in the
anxiolytic actions of GABAergic BZs has been suggested (Stein
et al., 1977; Thiebot et al., 1984; Harandi et al., 1987). Moreover,
studies have found that a decreased serotonin activity and turnover
emerges after the administration of BZs (Chase et al., 1970; Stein
et al., 1977; Pratt et al., 1979; Trulson et al., 1982; Wright et al.,
1992), although others have not found such effects (Shephard and
Broadhurst, 1982; Thiebot et al., 1984; Thiebot, 1986). Also, the
vast majority of serotonergic neurons express GABAA receptor α3-
subunit immunoreactivity but not GABAA receptor α1-subunit
staining (Gao et al., 1993). This is remarkable as the α1 subunit
is highly prevalent in the CNS. Thus, BZs could at least partially
produce their anxiolytic effects by activating α3 subunits located
on serotonergic neurons (Vinkers et al., 2010b). In support, sero-
tonergic raphe nuclei receive a prominent GABAergic input via
distant sources as well as interneurons (Harandi et al., 1987; Bagdy
et al., 2000; Gervasoni et al., 2000; Varga et al., 2001; Vinkers et al.,
2010b). Together, the interaction of the GABA and serotonin sys-
tem in anxiety disorders could be valuable in the search for novel
anxiolytic drugs. Nevertheless, the fact that BZs acutely reduce
anxiety, whereas SSRIs take several weeks before anxiolytic activ-
ity becomes apparent suggests that the two drug classes exert their
effects via different mechanisms.
TRANSLATIONAL STUDIES INTO ANXIETY
Can the data on the involvement of 5-HT in anxiety and anxi-
ety disorders (here illustrated with the 5-HTT, the 5-HT2 receptor
and the 5-HT1A receptor) be used to design translational research
that possibly will generate new hypotheses and targets for anxi-
olytic therapeutics? Recently, Jasinska et al. (2012) formulated a
hypothesis around the involvement of the 5-HTT gene, stress and
raphe–raphe interactions in order to try to explain the risk of
depression as a result of G × E interactions between the 5-HTT
gene and stress. Different populations of 5-HTergic neurons in the
dorsal raphe (DR) nucleus exist that differentially contribute to the
response to stress. As mentioned before differentiation of subpop-
ulations of 5-HT neurons could also be a factor contributing to
the development of anxiety disorders (Gaspar and Lillesaar, 2012;
Andrade andHaj-Dahmane, 2013). Although Jasinska et al. (2012)
hypothesize this mechanism mainly for depression, there is no a
priory reason why anxiety disorders would not be mediated by this
or a similarmechanism. The authors propose that the variability in
the reuptake of 5-HT during stressor-induced raphe–raphe inter-
actions alters the balance in amygdala–ventromedial prefrontal
cortex–DR (VMPFC–DR) circuitry. This VMPFC-DR circuitry
is important in the reactivity to stressors and the regulation of
emotion. In LL-individuals with an efﬁcient 5-HT transport the
circuitry is able to normalize, but not so in SS-individuals, poten-
tially leading to abnormal activity and pathology. Whether such
a mechanism also acts in human pathology is as yet unresolved
but could lead to speciﬁc searches for new mechanisms causing
pathological anxiety. Next to different functional 5-HTergic pop-
ulations in the DR, 5-HTTs appear very dynamically regulated
(Steiner et al., 2008), undergo regulated membrane trafﬁcking
as well as transitions between low and high activity states, with
many signaling pathways involved. Moreover, 5-HTT exhibits
dynamic associations with cytoskeletal binding proteins; actually
Chang et al. (2012) found two pools of 5-HTT proteins on the
surface of 5-HTergic cells, one relatively with free diffusion, the
other with restricted mobility due to binding to the cytoskeleton.
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Whether the 5-HTergic system exerts this kind of extremely vari-
ability which might lead to new and better understanding of the
role of the 5-HTT complex, including its genetic variability is
still a matter of the future but it remains fully possible that new
mechanisms involved in anxiety and its disorders might emerge.
CONCLUDING REMARKS
This review has illustrated the complexity of research on the
genetic background of anxiety disorders. Althoughwe discuss only
the serotonergic and the GABA system, more systems/candidates
are of potential interest including glutamate, NE, dopamine, and
some peptides (reviewed in Christmas et al., 2008), as well as
speciﬁc translocator protein which promote neurosteroidogene-
sis (Taliani et al., 2009; Nothdurfter et al., 2012) and agomelatine
(Stein et al., 2008). However, in the present review, four targets
have been presented to exemplify the complexity of anxiety: the
5-HT1A receptor, 5-HT2 receptor, 5-HTT, and GABAA recep-
tor. This is important as two known class of drugs (SSRIs and
BZs) are effective anxiolytics. Even though these anxiolytic drugs
have been around for decades, no subsequent breakthrough has
become available. The reasons for the relative lack of progress
in the anxiety ﬁeld are not completely clear but may be due to
the heterogeneous classiﬁcation of anxiety disorders, but also the
complex regulatory and ﬁnancial regulations in the ﬁnding of new
“druggable” targets (beyond the scope of this review, see, e.g.,
Knutsen, 2011). Nevertheless, a recurring theme is the contin-
ued paucity of novel targets for anxiolytic drugs and our limited
knowledge of the mechanisms underlying the various anxiety dis-
orders. This includes the limited contribution of genetic studies
to novel anxiolytic targets. In this review, we have argued that
it is vital to invest in fundamental research in the mechanisms
involved in anxiety processes in animals and unaffected individu-
als. Because a direct investigation of the human brain is often not
possible, animal research may contribute considerably in ﬁnding
neural substrates for anxiety and its pathology. However, it is not
realistic to think that such knowledge is completely translatable to
the clinical situation. Moreover, in animal models it is not always
possible to model speciﬁc symptoms related to human pathology,
which might cause limitations in the development of novel drug
targets.
The initial hope was, after elucidation of the human genome,
that the identiﬁcation of causative genes would be a matter of
time. Notwithstanding a certain degree of heritability of anxiety
disorders, no single gene or set of genes has emerged from a large
number of studies on large cohorts of patients thus far. It becomes
increasingly evident that anxiety disorders, probably similar to the
neurobiological mechanisms underlying anxiety processes, are the
result of many hundreds of genes with small effects which display
complex interactions with both environmental factors and other
genes. Therefore, genetic approaches in studies on anxiety disor-
ders may be enriched with preclinical studies to identify relevant
drug targets. It is improbable that a single gene contributes signif-
icantly to anxiety processes to a large degree. It is striking that the
functionality of GABA and 5-HT system in “normal” or “patho-
logical” anxiety in healthy individuals is largely unknown, In case
of 5-HT modulation (via 5-HT1A receptor activation or block-
ade of the 5-HTT) an indirect effect is possibly the most logical
explanation, because treatment of anxiety disorders with SSRIs or
buspirone takes weeks or even months before anxiolytic activity is
seen (acute effects seen after administration of these drugs are even
anxiogenic). The delayed effect therefore points to induction of
mechanisms that slowly change and need time to become effective
(plasticity changes). Anxiolytic effects after activation of GABAA
receptors seem acute and might point to a primary mechanism
directly involved in anxiety regulating mechanisms. Close collab-
oration between fundamental research and clinical studies into
the mechanisms underlying anxiety might lead to breakthroughs
in the search for novel anxiolytic drugs and enhance the success of
research and development efforts aimed at drug discovery for anx-
iety disorders. In conclusion, we argue that animal models should
play an important role in the future anxiolytic drugdevelopment as
a fundamental component of a broad multidisciplinary approach.
To be successful, novel clinical insights into the etiology of anx-
iety disorders from preclinical studies must be integrated in the
broader context of human genetic studies and novel biopathway
analysis.
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